Centre for Nanobiotechnology, Medical Biotechnology Division, School of Biosciences and Technology, VIT University, Vellore, 632014, Tamil Nadu, India.
Protoplasma. 2013 Jun;250(3):787-92. doi: 10.1007/s00709-012-0451-1. Epub 2012 Sep 12.
Gene therapy through antisense technology via intracellular delivery of a gene-silencing element is a promising approach to treat critical diseases like cancers. Ras acts as molecular switch, considered as one of the proto-oncogenes whose modification or mutation may promote tumor formation. The recent trends of nano-carrier-based drug delivery have gained superiority and proved to be 100 times more potent in drug delivery compared to standard therapies. The nano-based drug delivery has provided the basis of achieving successful target-specific drug delivery. Glutathione (GSH) is considered as one of the best and ubiquitous internal stimulus for swift destabilization of nano-transporters inside cells to accomplish proficient intracellular drug release. This concept has given a new hope to oncologists of modifying the existing drugs to be delivered to their desired destination. RNA interference is a primary tool in functional genomics to selectively silence messenger RNA (mRNA) expression, which can be exploited quickly to develop novel drugs against lethal disease target. Silencing of mRNA molecules using siRNA has also come of age to become one of the latest weapons developed in the concept of gene therapy. However, this strategy has severely failed to achieve target specificity especially to a tumor cell. In this context, we have proposed the incorporation of an antisense siRNA packed inside a GSH-responsive nano-transporter to be delivered specifically to a tumor cell against the sense mRNA of the Ras protein. It will limit the Ras-mediated activation of other proteins and transcription factors. Thus, it will knock down several differential gene expressions being regulated by Ras-activated pathways like enzyme-linked receptor kinase pathway. Henceforth, gene silencing technology through nano-drug delivery can be combined as a single weapon to terminate malignancy.
通过细胞内递送基因沉默元件的反义技术进行基因治疗是治疗癌症等重大疾病的一种有前途的方法。Ras 作为分子开关,被认为是原癌基因之一,其修饰或突变可能促进肿瘤形成。基于纳米载体的药物输送的最新趋势具有优势,并被证明在药物输送方面比标准疗法有效 100 倍。基于纳米的药物输送为实现成功的靶向药物输送提供了基础。谷胱甘肽 (GSH) 被认为是一种最佳且无处不在的内部刺激物,可迅速使纳米载体在细胞内失稳,从而有效地实现细胞内药物释放。这一概念为肿瘤学家提供了新的希望,即可以将现有药物进行修饰,使其能够送达所需的目标。RNA 干扰是功能基因组学中选择性沉默信使 RNA (mRNA) 表达的主要工具,可以快速开发针对致命疾病靶标的新型药物。使用 siRNA 沉默 mRNA 分子已经成熟,成为基因治疗概念中最新开发的武器之一。然而,这种策略在实现靶向特异性方面,特别是针对肿瘤细胞方面,严重失败。在这种情况下,我们提出将反义 siRNA 包裹在 GSH 响应性纳米载体中,专门递送至肿瘤细胞,以靶向 Ras 蛋白的有义 mRNA。这将限制 Ras 介导的其他蛋白质和转录因子的激活。因此,它将敲低由 Ras 激活途径(如酶联受体激酶途径)调节的几个差异基因表达。因此,通过纳米药物输送进行基因沉默技术可以结合作为单一武器来终止恶性肿瘤。